Mental health symptoms are a common and functionally impairing feature of rheumatoid arthritis, and increasingly seem to represent an integral part of the inflammatory process. Could treatment with DMARDs affect physical as well as mental health outcomes?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Savitz, J. & Harrison, N. A. Interoception and inflammation in psychiatric disorders. Biol. Psychiatry Cogn. Neurosci. Neuroimag. 3, 514–552 (2018).
Bullmore, E. The inflamed mind: A radical new approach to depression. (Short Books, London, 2018).
Matcham, F. et al. The impact of targeted rheumatoid arthritis pharmacological treatment on mental health: a systematic review and network meta-analysis. Arthritis Rheumatol. https://doi.org/10.1002/art.40565 (2018).
Matcham, F. et al. Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 17, 224 (2016).
Anderson, I. M. et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharm. 22, 343–396 (2008).
Turner, E. H. et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358, 252–260 (2008).
Tugwell, P. et al. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 26, 38 (2007).
Harrison, N. A. in Inflammation-Associated Depression: Evidence, Mechanisms and Implications (eds Dantzer, R. & Capuron, L.) 221–248 (Springer International, 2017).
Haapakoski, R. et al. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49, 206–215 (2015).
Miller, B. J. & Buckley, P. F. Monoclonal antibody immunotherapy in psychiatric disorders. Lancet Psychiatry 4, 13–15 (2017).
Acknowledgements
N.A.H. is in receipt of grant funding from the Wellcome Trust, the UK Medical Research Council, Arthritis Research UK (ARUK), Action for ME and Janssen pharmaceuticals. K.D. is in receipt of financial support from ARUK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.A.H. declares that he receives research funding support from Janssen pharmaceuticals and has acted as a paid consultant for GSK. K.D. declares no competing interests.
Rights and permissions
About this article
Cite this article
Harrison, N.A., Davies, K. DMARDs for mental health symptoms in RA. Nat Rev Rheumatol 14, 507–508 (2018). https://doi.org/10.1038/s41584-018-0063-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41584-018-0063-z
